At Nova International Diagnostics, we understand the importance of comprehensive prenatal screening to ensure the well-being of both expectant mothers and their unborn babies. Our Prenatal Marker Tests offer a range of screening options that aid in identifying potential genetic conditions and birth defects, allowing for early intervention and informed decision-making during pregnancy. With state-of-the-art technology and a team of skilled professionals, we are dedicated to providing accurate and reliable results, empowering parents with the knowledge they need for a healthier pregnancy journey.
Double Marker Test
Test description
The Double Marker Test is an early prenatal screening that evaluates two specific substances, Beta hCG (human chorionic gonadotropin) and PAPP-A (pregnancy-associated plasma protein A), in the expectant mother’s blood. This test is usually performed between 10 to 13.6 weeks of pregnancy and is highly effective in assessing the risk of chromosomal abnormalities, particularly Down syndrome (Trisomy 21).
Methodology
The Double Marker Test involves immunoassays and biochemical techniques to measure the levels of Beta hCG and PAPP-A in the blood and software for interpretation.
Intented Use
The primary application of the Double Marker Test is to identify the risk of Down syndrome (Trisomy 21) and other chromosomal abnormalities in the fetus, providing early insights into the pregnancy’s health.
Sample Collection and Submission
A simple blood sample is collected from the expectant mother.
Most recent USG report is required.
Our laboratory ensures a smooth and efficient sample submission process, providing detailed instructions for proper sample collection and transportation to the laboratory.
Triple Marker Test
Test description
The Triple Marker Test is a prenatal screening that evaluates three specific substances, Alpha-fetoprotein (AFP), Beta hCG, and Estriol, in the mother’s blood. Typically performed between 15 to 20 weeks of pregnancy, this test helps assess the risk of chromosomal abnormalities and neural tube defects in the developing fetus.
Methodology
The Triple Marker Test involves immunoassays and biochemical techniques to measure the levels of AFP, Beta hCG, and Estriol in the blood.
Intented Use
The Triple Marker Test is instrumental in detecting the risk of Down syndrome (Trisomy 21) Trisomy 18 (Edward) and Trisomy 13 (Patau) as well as neural tube defects in the fetus.
Sample Collection and Submission
A blood sample is collected from the expectant mother.
A recent USG report is required.
Our laboratory ensures a seamless sample submission process, providing detailed instructions for proper sample collection and transportation to the laboratory.
Quadruple Marker Test
Test description
The Quadruple Marker Test is a prenatal screening that analyzes four substances in the mother’s blood: AFP, β-hCG, estriol, and inhibin-A. Typically performed between 15 to 20 weeks of pregnancy, this test provides a more comprehensive assessment of the risk of chromosomal abnormalities and neural tube defects in the fetus.
Methodology
Immunoassays and software interpretation.
Intented Use
Assessing the risk of Down syndrome (Trisomy 21), Trisomy 18 (Edward) and Trisomy 13 (Patau) and neural tube defects.
Sample Collection and Submission
A blood sample is collected from the expectant mother.
A recent USG report is required.
Our laboratory ensures a seamless sample submission process, providing detailed instructions for proper sample collection and transportation to the laboratory.
At Nova International Diagnostics, we offer not only comprehensive prenatal marker tests but also a wide range of endocrinological hormonal tests. These tests help assess hormone levels, identify hormonal imbalances, and aid in the diagnosis and management of various endocrine disorders. With advanced technology and expert analysis, our endocrinological hormonal tests provide valuable insights into the overall hormonal health of our patients, contributing to better health outcomes and improved quality of life.